Application of the yeast Yarrowia lipolytica as a model to analyse human pathogenic mutations in mitochondrial complex I (NADH:ubiquinone oxidoreductase)

被引:30
作者
Kerscher, S [1 ]
Grgic, L [1 ]
Garofano, A [1 ]
Brandt, U [1 ]
机构
[1] Goethe Univ Frankfurt, Fachbereich Med, Inst Biochem 1, ZBC, D-60590 Frankfurt, Germany
来源
BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS | 2004年 / 1659卷 / 2-3期
关键词
Yarrowia lipolytica; mutation; complex I;
D O I
10.1016/j.bbabio.2004.07.006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
While diagnosis and genetic analysis of mitochondrial disorders has made remarkable progress, we still do not understand how given molecular defects are correlated to specific patterns of symptoms and their severity. Towards resolving this dilemma for the largest and therefore most affected respiratory chain enzyme, we have established the yeast Yarrowia lipolytica as a eucaryotic model system to analyse respiratory chain complex I. For in vivo analysis, eYFP protein was attached to the 30-kDa subunit to visualize complex I and mitochondria. Deletions strains for nuclear coded subunits allow the reconstruction of patient alleles by site-directed mutagenesis and plasmid complementation. In most of the pathogenic mutations analysed so far, decreased catalytic activities, elevated K-M values, and/or elevated 150 values for quinone-analogous inhibitors were observed, providing plausible clues on the pathogenic process at the molecular level. Leigh mutations in the 49-kDa and PSST homologous subunits are found in regions that are at the boundaries of the ubiquinone-reducing catalytic core. This supports the proposed structural model and at the same time identifies novel domains critical for catalysis. Thus, Y. lipolytica is a useful lower eucaryotic model that will help to understand how pathogenic mutations in complex I interfere with enzyme function. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:197 / 205
页数:9
相关论文
共 36 条
[31]   Anti-cancer analogues ME-143 and ME-344 exert toxicity by directly inhibiting mitochondrial NADH: ubiquinone oxidoreductase (Complex I) [J].
Lim, Sze Chern ;
Carey, Kirstyn T. ;
McKenzie, Matthew .
AMERICAN JOURNAL OF CANCER RESEARCH, 2015, 5 (02) :689-701
[32]   Kinetics of transhydrogenase reaction catalyzed by the mitochondrial NADH-ubiquinone oxidoreductase (Complex I) imply more than one catalytic nucleotide-binding sites [J].
Zakharova, NV ;
Zharova, TV ;
Vinogradov, AD .
FEBS LETTERS, 1999, 444 (2-3) :211-216
[33]   THE GENE LOCUS OF THE PROTON-TRANSLOCATING NADH - UBIQUINONE OXIDOREDUCTASE IN ESCHERICHIA-COLI - ORGANIZATION OF THE 14 GENES AND RELATIONSHIP BETWEEN THE DERIVED PROTEINS AND SUBUNITS OF MITOCHONDRIAL COMPLEX-I [J].
WEIDNER, U ;
GEIER, S ;
PTOCK, A ;
FRIEDRICH, T ;
LEIF, H ;
WEISS, H .
JOURNAL OF MOLECULAR BIOLOGY, 1993, 233 (01) :109-122
[34]   Decreased expression of the NADH:ubiquinone oxidoreductase (complex I) subunit 4 in 1-methyl-4-phenylpyridinium-treated human neuroblastoma SH-SY5Y cells [J].
Conn, KJ ;
Ullman, MD ;
Eisenhauer, PB ;
Fine, RE ;
Wells, JM .
NEUROSCIENCE LETTERS, 2001, 306 (03) :145-148
[35]   Analysis of Human Clinical Mutations of Mitochondrial ND1 in a Bacterial Model System for Complex I [J].
Alkhaldi, Hind A. A. ;
Phan, Duong H. H. ;
Vik, Steven B. B. .
LIFE-BASEL, 2022, 12 (11)
[36]   Insights into the pathogenic character of a common NUBPL branch-site mutation associated with mitochondrial disease and complex I deficiency using a yeast model [J].
Wydro, Mateusz M. ;
Balk, Janneke .
DISEASE MODELS & MECHANISMS, 2013, 6 (05) :1279-1284